Next Article in Journal
rs622342 in SLC22A1, CYP2C9*2 and CYP2C9*3 and Glycemic Response in Individuals with Type 2 Diabetes Mellitus Receiving Metformin/Sulfonylurea Combination Therapy: 6-Month Follow-Up Study
Previous Article in Journal
Risk Factors Associated with Low Back Pain among A Group of 1510 Pregnant Women
Open AccessArticle

Correlation between F18-FDG PET/CT Imaging and BRAF V600E Genetic Mutation for the Early Assessment of Treatment Response in Papillary Thyroid Cancers

by Andra Piciu 1,†, Maria-Iulia Larg 2,*,† and Doina Piciu 2,3,†
1
Department of Medical Oncology Iuliu Hațieganu, University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania
2
Department of Endocrine Tumors and Nuclear Medicine, Institute of Oncology “Prof.dr.Ion Chiricuță” 400015 Cluj-Napoca, Romania
3
PhD School Iuliu Hațieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania
*
Author to whom correspondence should be addressed.
All authors have equally contributed to this work.
J. Pers. Med. 2020, 10(2), 52; https://doi.org/10.3390/jpm10020052
Received: 3 June 2020 / Revised: 11 June 2020 / Accepted: 18 June 2020 / Published: 19 June 2020
(This article belongs to the Special Issue Present and Future of Personalised Medicine for Endocrine Cancers)
In thyroid neoplastic pathology, the BRAF V600E mutation is shown to be involved in the oncogenesis of papillary thyroid cancer and its subtypes. The purpose of this study is to evaluate the correlation between the mutation of the BRAF V600E oncogene and the pathological standardized uptake values (SUV) at the F18-fluorodeoxyglucose (F18-FDG) positron emission tomography/computed tomography (PET/CT) evaluation, for a group of 20 patients with radically treated (total thyroidectomy and radioiodine therapy) papillary thyroid cancer, with subclinical persistent disease, at 6 months after the initial treatment. We analyzed the correlations between the values of SUV and the presence of the BRAF mutation as well with other prognostic factors such as stage, age, specific tumor markers (thyroglobulin and anti-thyroglobulin), extrathyroid extension, the presence of metastatic lymph nodes or distant metastasis. The value of SUV in the case of BRAF+ (positive) patients was higher than in the negative ones, but without statistical significance, thus, the values of the SUV cannot be a predictable factor for the presence of the genetic mutation. There was a statistically significant correlation in BRAF+ subgroup between the SUV values and the positive resection limit following surgery, showing a higher SUV value in the PET/CT evaluation. No correlation was observed between the aforementioned prognostic factors involved in papillary thyroid cancer and the BRAF V600E mutation. View Full-Text
Keywords: papillary thyroid cancer; SUV PET/CT; BRAF V600E papillary thyroid cancer; SUV PET/CT; BRAF V600E
Show Figures

Figure 1

MDPI and ACS Style

Piciu, A.; Larg, M.-I.; Piciu, D. Correlation between F18-FDG PET/CT Imaging and BRAF V600E Genetic Mutation for the Early Assessment of Treatment Response in Papillary Thyroid Cancers. J. Pers. Med. 2020, 10, 52.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop